Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. Founded in 2014, Compass focuses on developing proprietary antibody-based therapeutics to treat a variety of human diseases, with a strong emphasis on oncology.
The company’s core mission is to thoroughly address the tumor-immune synapse by utilizing combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass industrializes antibody discovery and decentralizes biologic validation through a partnership-first mentality, leveraging best-in-class technologies and top-tier academic laboratories globally. All novel scientific insights are validated extensively within Compass's own labs before proceeding to proprietary combination therapeutics aimed at human clinical trials.
In 2015, Compass secured a $120 million Series A financing to support its ambitious plans to build a fully-integrated biopharmaceutical company. The company’s robust pipeline includes three primary product candidates—CTX-009, CTX-471, and CTX-8371. CTX-009 is a bispecific antibody combining DLL4 and VEGF-A inhibitors, CTX-471 is a CD137 agonist, and CTX-8371 is a PD-1 x PD-L1 bispecific antibody. These candidates are in various stages of clinical development, targeting key pathways in angiogenesis, immune response activation, and immunosuppressive mechanisms within the tumor microenvironment.
Recently, Compass has achieved significant milestones. The company reported top-line data showing promising results in its Phase 2 COMPANION-003 trial and Phase 2/3 COMPANION-002 trial. Additionally, the FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for metastatic or locally advanced biliary tract cancer. Compass continues to make strides in advancing its product candidates through both standalone therapies and combinations with its proprietary pipeline antibodies.
Financially, Compass maintains a strong position, with a year-end 2023 cash balance of $152 million, extending its cash runway into mid-2026. The company’s net loss for 2023 was $42.5 million, showing a slight increase from the previous year, reflecting its intensified clinical and manufacturing activities.
Looking forward, Compass plans to continue its clinical trials and explore additional therapeutic areas. Key leadership changes and additions, such as the appointment of Vered Bisker-Leib, PhD, as CEO, reflect the company’s commitment to steering towards innovation and growth.
For more detailed and updated information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on cancer treatment, will participate in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York City. The company's presentation is scheduled for December 1, 2022, at 8:50 AM ET. A webcast link will be available on their website, and the corporate presentation will be archived for 90 days. Compass Therapeutics is dedicated to developing antibody-based therapies targeting key biological pathways to enhance anti-tumor responses.
Compass Therapeutics (CMPX) announced financial results for Q3 2022, reporting a net loss of $12 million, or $0.12 per share, compared to $6 million, or $0.10 per share, in Q3 2021. Cash and marketable securities were $120.6 million, down from $144.5 million at the end of 2021. The company raised approximately $80 million through a PIPE financing to extend its cash runway into 2026. Key clinical trials for CTX-009 and CTX-471 are underway, with patient enrollment expected to start in Q4 2022. R&D expenses surged by 210% year-over-year, reflecting increased development activities.
BOSTON, Nov. 08, 2022 - Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in two key investor conferences this November. The Stifel Healthcare Conference in New York City is scheduled for November 15, 2022, from 4:10-4:40 PM ET. The Jefferies Global Healthcare Conference in London will take place on November 16, 2022, from 3:15-3:45 PM GMT. Both presentations will be available via webcast, with a replay accessible for 90 days. Compass Therapeutics focuses on developing antibody-based therapies targeting cancer.
Compass Therapeutics, Inc. (CMPX) announced a private investment in public equity (PIPE) financing, selling 25 million shares at $3.21 each, totaling approximately $80 million. The financing, led by Enavate Sciences and other institutional investors, is expected to close by November 8, 2022. Funds will advance their clinical pipeline, including CTX-009, CTX-471, and CTX-8371, extending the company's cash runway into 2026. The securities have not been registered under the Securities Act but will be subject to a registration rights agreement for resale.
Compass Therapeutics (Nasdaq: CMPX) announced a clinical trial collaboration with Merck to evaluate its monoclonal antibody CTX-471 in combination with KEYTRUDA® for treating advanced cancers post anti-PD-1 therapy. The Phase 1b trial will enroll patients with various cancer types and assess safety, pharmacokinetics, and clinical activity. Initial results from earlier trials showed partial responses in patients. This collaboration marks a significant advancement in cancer immunotherapy.
Compass Therapeutics (Nasdaq: CMPX) announced its participation in the 24th Annual H.C. Wainwright Global Investment Conference in New York City, scheduled for September 12 – 14, 2022. The company's presentation is set for September 13, 2022, at 2:30 PM EDT. A webcast of the presentation will be available and archived on their Events page for 90 days.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will present at the 2022 Wedbush PacGrow Healthcare Conference, scheduled virtually for August 9-10, 2022. The presentation is set for August 9 at 4:05 pm ET. Interested parties can access the webcast here, and it will be available for replay for 90 days on Compass’s Events page.
Compass Therapeutics focuses on developing antibody-based therapeutics aimed at treating cancer by targeting critical biological pathways.
Compass Therapeutics (CMPX) reported Q2 2022 results with a net loss of $8.5M ($0.08/share), down from $55.8M ($1.07/share) in Q2 2021. Cash and marketable securities totaled $132M, extending their runway into H2 2024. The company is set to initiate a Phase 2/3 trial for CTX-009 in biliary tract cancer (BTC) and a Phase 2 trial for advanced colorectal cancer (CRC) by Q4 2022. Additionally, CTX-471 continues to show efficacy in mesothelioma patients, with four reported partial responses. R&D expenses rose to $5.9M from $2.9M, while G&A expenses increased to $3.1M from $2.2M, reflecting ongoing operational growth.
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, will present at the 2022 Jefferies Global Healthcare Conference on June 9, 2022, at 8:00 am ET in New York City. The presentation will focus on the company's proprietary antibody-based cancer therapeutics. It will be available for live streaming and archived for 90 days on their website. Compass Therapeutics aims to advance innovative therapies targeting critical biological pathways in oncology.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the 2022 H.C. Wainwright Global Investment Conference from May 23-26, 2022. The webinar will be available on-demand starting May 24, 2022, at 7:00 a.m. ET, and can be accessed through their website. Compass Therapeutics is dedicated to developing therapies targeting angiogenesis and immune response mechanisms to combat tumors, with a pipeline aimed at advancing multiple product candidates.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
What does Compass Therapeutics, Inc. specialize in?
What are the main product candidates of Compass Therapeutics?
What recent milestones has Compass Therapeutics achieved?
Where is Compass Therapeutics headquartered?
How is Compass Therapeutics financed?
Who are the key executives at Compass Therapeutics?
What is the scientific focus of Compass Therapeutics?
What is the financial condition of Compass Therapeutics?
How does Compass Therapeutics innovate in antibody discovery?
What therapeutic areas is Compass Therapeutics exploring?
